Kidney Disease News and Research

RSS
Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

UH researchers identify new method to provide diagnostic information on kidney disease

UH researchers identify new method to provide diagnostic information on kidney disease

Measuring kidney function and damage may help predict people at risk for heart disease

Measuring kidney function and damage may help predict people at risk for heart disease

First European approval of drug to treat genetic kidney disease ADPKD

First European approval of drug to treat genetic kidney disease ADPKD

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

DaVita Clinical Research announces expansion of clinical trials capabilities in Europe

DaVita Clinical Research announces expansion of clinical trials capabilities in Europe

CVRx announces presentation of positive data from Barostim Therapy for Heart Failure clinical trial at HRS 2015

CVRx announces presentation of positive data from Barostim Therapy for Heart Failure clinical trial at HRS 2015

Breakthrough in fight against rare kidney disease - Membranous Nephropathy

Breakthrough in fight against rare kidney disease - Membranous Nephropathy

Sheffield scientists to showcase novel medical discoveries during International Clinical Trials Day

Sheffield scientists to showcase novel medical discoveries during International Clinical Trials Day

Wearable diagnostic machines presented at Elsevier's 4th International Conference on Bio-Sensing Technology

Wearable diagnostic machines presented at Elsevier's 4th International Conference on Bio-Sensing Technology

New Johns Hopkins-led research suggests risk factors for developing acute kidney injury

New Johns Hopkins-led research suggests risk factors for developing acute kidney injury

Raising lupus awareness: an interview with Professor Ramsey-Goldman, MD

Raising lupus awareness: an interview with Professor Ramsey-Goldman, MD

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

Bone-marrow-derived MSCs can promote fracture healing

Bone-marrow-derived MSCs can promote fracture healing

New genetic mutation appears to protect people from Type 2 diabetes

New genetic mutation appears to protect people from Type 2 diabetes

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Study shows NASH linked to 50% higher death rates compared with NAFLD

Study shows NASH linked to 50% higher death rates compared with NAFLD

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.